ADMA Biologics Inc (NASDAQ:ADMA) Given Average Recommendation of “Hold” by Brokerages

ADMA Biologics Inc (NASDAQ:ADMA) has been given a consensus recommendation of “Hold” by the six research firms that are presently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $18.6667.

Several equities research analysts have recently weighed in on ADMA shares. Mizuho decreased their price target on ADMA Biologics from $20.00 to $17.00 and set an “outperform” rating for the company in a research note on Wednesday, July 15th. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Canaccord Genuity Group lowered their price target on shares of ADMA Biologics from $21.00 to $18.00 and set a “buy” rating for the company in a report on Thursday, May 7th. Weiss Ratings restated a “hold (c)” rating on shares of ADMA Biologics in a research report on Thursday, June 18th. Finally, Zacks Research downgraded shares of ADMA Biologics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 4th.

Hedge Funds Weigh In On ADMA Biologics

Several hedge funds and other institutional investors have recently bought and sold shares of ADMA. Summit Securities Group LLC bought a new stake in ADMA Biologics during the fourth quarter valued at $29,000. Western Wealth Management LLC bought a new position in shares of ADMA Biologics in the 1st quarter worth about $31,000. iSAM Funds UK Ltd acquired a new position in shares of ADMA Biologics in the 3rd quarter valued at about $34,000. Morse Asset Management Inc bought a new stake in shares of ADMA Biologics during the 4th quarter valued at about $44,000. Finally, Nkcfo LLC bought a new stake in shares of ADMA Biologics during the 4th quarter valued at about $47,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Price Performance

Shares of NASDAQ:ADMA opened at $9.84 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.81 and a current ratio of 6.97. ADMA Biologics has a 52 week low of $7.21 and a 52 week high of $20.46. The firm has a market cap of $2.20 billion, a PE ratio of 14.06 and a beta of 0.74. The firm’s fifty day moving average is $8.96 and its 200-day moving average is $10.79.

ADMA Biologics (NASDAQ:ADMA) last posted its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.16 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.16. The business had revenue of $124.39 million during the quarter, compared to the consensus estimate of $125.34 million. ADMA Biologics had a return on equity of 40.17% and a net margin of 32.98%.ADMA Biologics’s quarterly revenue was up 2.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.14 earnings per share. Sell-side analysts predict that ADMA Biologics will post 0.78 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.